Bank of New York Mellon Corp lowered its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 13.5% in the ...

Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

Shares of 10x Genomics, Inc. (NASDAQ:TXG – Get Free Report) have received a consensus rating of “Hold” from the seventeen analysts that are currently covering the company, Ratings reports. One ...

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East ...

Nashville Biosciences LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center, and global DNA sequencing giant Illumina Inc.

Genmab A/S announced today updated data from cohort B1 of the Phase 1/2 RAINFOL-01 study of rinatabart sesutecan (Rina-S®), an investigational folate receptor-alpha (FR?)-targeted, TOPO1 antibody-drug ...

PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced a newly published study in Nature Communications unveiling a powerful new method for ...

After hours: March 20 at 7:55:44 PM EDT Loading Chart for TXG ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...